LTR Pharma (ASX:LTP) Dividend Payout Ratio : 0.00 (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Dividend Payout Ratio?

LTR Pharma's dividend payout ratio for the months ended in Jun. 2023 was 0.00.

The historical rank and industry rank for LTR Pharma's Dividend Payout Ratio or its related term are showing as below:

ASX:LTP's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.44
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-06-07), the Dividend Yield % of LTR Pharma is 0.00%.

LTR Pharma's Dividends per Share for the months ended in Jun. 2023 was A$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

LTR Pharma Dividend Payout Ratio Historical Data

The historical data trend for LTR Pharma's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Dividend Payout Ratio Chart

LTR Pharma Annual Data

Trend

Jun21

Jun22

Jun23

Dividend Payout Ratio

LTR Pharma Semi-Annual Data
	Jun21	Jun22	Jun23
Dividend Payout Ratio	-	-	-

Competitive Comparison of LTR Pharma's Dividend Payout Ratio

For the Biotechnology subindustry, LTR Pharma's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LTR Pharma's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where LTR Pharma's Dividend Payout Ratio falls into.

LTR Pharma Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

LTR Pharma's Dividend Payout Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Jun. 2023 )	/	EPS without NRI (A: Jun. 2023 )
	=	0	/	-0.01
	=	N/A

LTR Pharma's Dividend Payout Ratio for the quarter that ended in Jun. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2023 )	/	EPS without NRI (Q: Jun. 2023 )
	=	0	/	-0.01
	=	N/A

LTR Pharma (ASX:LTP) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

LTR Pharma Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

9A/204 Alice Street, Brisbane, QLD, AUS, 4000

Website

https://www.ltrpharma.com

LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines